ROCKVILLE, Md., Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of...
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments